Play­ing catch-up, Re­gen­eron and Sanofi push ahead on piv­otal PD-1 can­cer stud­ies

Re­gen­eron $REGN is wast­ing no time in push­ing ahead with what it hopes is their first piv­otal study for the lat­est in what is be­com­ing a long line of PD-1 check­point drugs. In its earn­ings re­lease this morn­ing the big biotech says that it is re­cruit­ing pa­tients for a po­ten­tial reg­is­tra­tion Phase II study on ad­vanced cu­ta­neous squa­mous cell car­ci­no­ma.

ISI an­a­lyst Mark Schoenebaum added in a note this morn­ing that he’s keep­ing a close eye on their Phase II for non-small cell lung can­cer, which al­so launch­es this year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.